Lido Advisors
CADL icon

Lido Advisors’s Candel Therapeutics CADL Stock Holding History

Lido Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$563K Sell
54,650
-5,607
-9% -$42.4K ﹤0.01% 1404
2026
Q1 		$295K Buy
60,257
+56
+0.1% +$305 ﹤0.01% 1572
2025
Q4 		$307K Hold
60,201
– – ﹤0.01% 1557
2025
Q3 		$307K Buy
+60,201
New +$348K ﹤0.01% 1478

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lido Advisors's CADL Position: Q2 2026 in Review

Lido Advisors reduced its Candel Therapeutics (CADL) stake by 9.3% in Q2 2026, selling an estimated $42.4K and leaving 54,650 shares worth $563K. The position accounts for ﹤0.01% of the portfolio, ranked #1404.

Lido Advisors first reported a position in CADL in Q3 2025 and has held it in 4 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Lido Advisors held 54,650 shares of Candel Therapeutics worth $563K as of Q2 2026.
  • Lido Advisors sold 5,607 Candel Therapeutics shares in Q2 2026, an estimated $42.4K.
  • Candel Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1404 holding.
  • Lido Advisors first reported a position in Candel Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.